Lisata Therapeutics宣布:自2026年8月3日起,终止Kristen K. Buck研发执行副总裁兼首席医疗官职务——SEC文件披露

美股速递
Aug 04

Lisata Therapeutics(公司名:LISATA THERAPEUTICS INC)——据美国证券交易委员会(SEC)最新提交的文件显示,该公司已正式决定,自2026年8月3日起,终止Kristen K. Buck担任的研发执行副总裁(Evp of R&D)兼首席医疗官(Chief Medical Officer)职务。此举标志着公司高层管理团队的重大调整。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10